Bioequivalence studies of Sildenafil suspension and Sildenafil Immediate Release
• Sildenafil is the drug that can treat erectile dysfunction in human men. The clinical bioequivalence studies the drug in lower doses can also treat Pulmonary Arterial Hypertension (PAH) in human beings. The sponsorship of this drug bioequivalence studies are Pfizer pharmaceutical company.
• The clinical studies between Sildenafil oral suspension and Sildenafil immediate release tablet. The concentration of the Sildenafil oral suspension is 10 mg/ml; while Sildenafil citrate immediate release is with the dosage of 10 mg and 20 mg.
• The studies are done by allocation and randomization; masking is done by open-label and the purpose of clinical studies is for the treatment of erectile dysfunction.
• Drug information; the drug is highly potent it can treat by causing erections for about 4 hours and best required for the erectile dysfunction.
• The pharmacokinetics of this drug Sildenafil; can be explained as, area under curve (AUC) are with zero levels of plasma concentrations. The time period of the measurable concentrations are should be maintained for 12, and 14 hours.
• The secondary outcomes of the drug formulations are zero to time infinity. The healthy volunteers that are with the ages 18-55 years. Both females and males are eligible to this clinical trail.
• The criteria that are responsible for these clinical trails are the abnormalities of the volunteers, medical history and pother4 physical examination. The physical examination includes the Body Mass Index, and total body weight.
• The Sildenafil citrate immediate release will help in maintaining the erections and also treats Pulmonary Arterial hypertension.